Calithera Biosciences (CALA) Commences Underwritten Public Offering of Common

Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs for the treatment of cancer and other life-threatening diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares of common stock are being offered by Calithera. Citigroup is acting as sole book-running manager for the offering. In connection with this offering, Calithera expects to grant Citigroup a 30-day option to purchase an additional 15% of the shares of common stock offered in the public offering.

The offering is subject to market conditions, as well as Nasdaq approval, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

You May Also Be Interested In

• Huang Calls AI 'the Great Equalizer' During G20 Event
• Manulife prices $750M subordinated notes offering at 6.146%
• Ford Motor August U.S. Sales 170,681 Vehicles, Down 10.3%